Presence of HIV-1 Nef specific CD4 T cell response is associated with non-progression in HIV-1 infection

Vaccine

Volumn 25, Issue 31, 2007, Pages 5927-5937

  Pancré, Véronique ^a   Delhem, Nadira ^a   Yazdanpanah, Yazdan ^b   Delanoye, Anne ^a   Delacre, Myriam ^a   Depil, Stéphane ^a   Moralès, Olivier ^a   Mouton, Yves ^b   Auriault, Claude ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

^b CENTRE HOSPITALIER DE TOURCOING   (France)

Author keywords

CD4 epitope; Peptide; Protection

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GAMMA INTERFERON; HLA DQ ANTIGEN; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; NEF PROTEIN; PEPTIDE DERIVATIVE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

CD4-POSITIVE T-LYMPHOCYTES; DISEASE PROGRESSION; GENE PRODUCTS, NEF; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL;

EID: 34447270549     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.05.038     Document Type: Article

References (29)

1. + T cell responses associated with control of viremia. Science 278 (1997) 1447-1450
2. Kalams S.A., Buchbinder S.P., Rosenberg E.S., Billingsley J.M., Colbert D.S., Jones N.G., et al. Association between virus-specific cytotoxic T lymphocyte and helper responses in Human Immunodeficiency Virus type-1 infection. J Virol 73 (1999) 6715-6720
3. Clerici M., Balotta C., Meroni L., Ferrario E., Riva C., Trabattoni D., et al. Type 1 cytokine production and low prevalence of viral isolation correlate with Long-Term Nonprogression in HIV-infection. AIDS Res Hum Retroviruses 12 (1996) 1053-1061
4. Harrer T., Harrer E., Kalams S.A., Elbeik T., Staprans S.I., Feinberg M.B., et al. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable non-progressing HIV type 1 infection. AIDS Res Hum Retroviruses 12 (1996) 585-592
5. Jansen C.A., De Cuyper I.M., Steingrover R., Jurriaans S., Sankatsing S.U., Prins J.M., et al. Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 functions. AIDS 19 (2005) 1145-1154
6. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 182 (2000) 792-798
7. Musey L.K., Krieger J.N., Hugues J.P., Schacker T.W., Corey L., and McElrath M.J. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection. J Infect Dis 180 (1999) 278-284
8. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med 5 (1999) 518-525
9. + T cells. Nature 417 (2002) 95-98
10. + T cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med 3 (1997) 533-540
11. Pontesilli O., Carotenuto P., Kerkhof-Garde S.R., Roos M.T., Keet I.P., Coutinho R.A., et al. Lymphoproliferative response to HIV-1 p24 in long-term survivors of HIV-1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses 15 (1999) 973-981
12. + CD4 T cell responses is associated with nonprogression in HIV-1 infection. J Immunol 169 (2002) 6376-6385
13. Sommerfelt M.A., Nyhus J., and Sorensen B. Novel peptide-based HIV-1 immunotherapy. Expert Opin Biol Ther 4 (2004) 349-361
14. + T cells. Clin Exp Immunol 129 (2002) 429-437
15. Bian H., and Hammer J. Discovery of promiscuous HLA-II-restricted T cell epitopes with TEPITOPE. Methods 34 (2004) 468-475
16. Gahéry-Ségard H., Pialoux G., Charmeteau B., Serme S., Poncelet H., Raux M., et al. Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J Virol 74 (2000) 1694-1703
17. Hinkula J., Svanholm C., Schwartz S., Lundholm P., Brytting M., Engstrom G., et al. Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol 71 (1997) 5528-5539
18. Berzofsky J.A. Epitope selection and design of synthetic vaccine: molecular approaches to enhancing immunogenicity and cross-reactivity of engineered vaccines. Ann NY Acad Sci 690 (1993) 256-263
19. Bourinbaiar A.S., Root-Bernstein R.S., Abulafia-Lapid R., Rytik P.G., Kanev A.N., Jirathitikal V., et al. Therapeutic AIDS vaccines. Curr Pharm Des (2006) 2017-2030
20. Berzofsky J.A., Ahlers J.D., and Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol (2001) 209-219
21. Ahlers J.D., Belyakov I.M., Thomas E.K., and Berzofsky J.A. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J Clin Inf 108 (2001) 1677-1685
22. Okazaki T., Pendleton C.D., Sarobe P., Thomas E.K., Iyengar S., Harro C., et al. Epitope enhancement of a CD4 HIV epitope toward the development of the next generation HIV vaccine. J Immunol 176 (2006) 3753-3759
23. Kaufmann D.E., Bailey P.M., Sidney J., Wagner B., Noris P.J., Johnston M.N., et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of Gag and Nef and the presence of broadly recognized peptides. J Virol 78 (2004) 4463-4477
24. Sousa A.E., Chaves A.F., Loureiro A., and Victorino R.M. Comparison of the frequency of Interleukin (IL-2), interferon-gamma, and IL-4 producing T cells in 2 disease, human immunodeficiency virus types 1 and 2, with distinct clinical outcomes. J Infect Dis 184 (2001) 552-559
25. Sieg S.F., Bazdar D.A., Harding C.V., and Lederman M.M. Differential expression of interleukin-2 and gamma interferon in human immunodeficiency virus disease. J Virol 75 (2001) 9983-9985
26. Peretz Y., Alter G., Boisvert M.P., Hatzakis G., Tsoukas C.M., and Bernard N.F. Human immunodeficiency virus (HIV)-specific gamma interferon secretion directed against all expressed HIV genes: relationship to rate of CD4 decline. J Virol 79 (2005) 4908-4917
27. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126 (1997) 946-954
28. + T-cell responses for progression to AIDS analysed in a prospective cohort study. Blood 107 4 (2006) 1427-1433
29. Duerr A., Wasserheit J.N., and Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 43 (2006) 500-511